Literature DB >> 23493637

Molecular Analysis of A2-genes Encoding Stage-specific S Antigen-like Proteins among Isolates from Iranian Cutaneous and Visceral Leishmaniasis.

Mahin Farahmand1, Hasti Atashi Shirazi, Hossein Nahrevanian, Homa Hajjaran.   

Abstract

OBJECTIVES: Leishmania can lead to a broad spectrum of diseases, collectively known as leishmaniasis. The A2 gene/ protein family could be one of the most eligible candidate factors of virulence in visceral leishmaniasis (VL). The previous results confirmed that in Leishmania infantum, several A2 proteins are abundantly expressed by the amastigote, but not the promastigote stage. As there are no data available on the pattern of A2 gene / protein in Iranian Leishmania isolates of either cutaneous leishmaniasis (CL) or VL; the current study aimed to investigate molecular analysis of A2 gene in leishmania species among field isolates of .
MATERIALS AND METHODS: An A2 gene was identified by sequencing of crude PCR products resulting from 20 samples of CL and 10 samples of VL isolates from Iranian patients.
RESULTS: The results indicated the A2 gene in CL is only a single copy of 153 bp encoding a protein of 51 amino acids, as opposed to A2 of VL species with multi-copy genes of varying length. A2 sequences in Iranian L. major strains represented a homology with stage-specific S antigen-like protein (A2) of L. major and L. infantum. Moreover, A2 sequences in Iranian L. tropica strains have homology with A2 protein of L. major and L. tropica.
CONCLUSION: It is concluded that A2 is an antigen candidate for vaccine development and diagnosis purposes and that A2 sequences are conserved among field isolates.

Entities:  

Keywords:  A2protein; Iran; L .major; L .tropica; L. infantum; Leishmania

Year:  2011        PMID: 23493637      PMCID: PMC3586840     

Source DB:  PubMed          Journal:  Iran J Basic Med Sci        ISSN: 2008-3866            Impact factor:   2.699


  25 in total

1.  Expression of A2 proteins in amastigotes of Leishmania infantum produced from canine isolates collected in the district of Meshkinshahr, in north-western Iran.

Authors:  M Farahmand; H Nahrevanian; M Assmar; M Mohebali; Z Zarei
Journal:  Ann Trop Med Parasitol       Date:  2008-01

2.  Evaluation of PCR assay in diagnosis and identification of cutaneous leishmaniasis: a comparison with the parasitological methods.

Authors:  Farideh Shahbazi; Saed Shahabi; Bahram Kazemi; Mehdi Mohebali; Ali Reza Abadi; Zabiholah Zare
Journal:  Parasitol Res       Date:  2008-07-25       Impact factor: 2.289

3.  Leishmania donovani heat shock protein 100. Characterization and function in amastigote stage differentiation.

Authors:  S Krobitsch; S Brandau; C Hoyer; C Schmetz; A Hübel; J Clos
Journal:  J Biol Chem       Date:  1998-03-13       Impact factor: 5.157

4.  Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis.

Authors:  E Ghedin; W W Zhang; H Charest; S Sundar; R T Kenney; G Matlashewski
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

5.  Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.

Authors:  Hossein Nahrevanian; Mahin Farahmand; Zohreh Aghighi; Mehdi Assmar; Aref Amirkhani
Journal:  Exp Parasitol       Date:  2007-01-19       Impact factor: 2.011

6.  Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene.

Authors:  H Charest; G Matlashewski
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

7.  Identification and overexpression of the A2 amastigote-specific protein in Leishmania donovani.

Authors:  W W Zhang; H Charest; E Ghedin; G Matlashewski
Journal:  Mol Biochem Parasitol       Date:  1996-06       Impact factor: 1.759

8.  Detection of Leishmania infantum kinetoplast DNA in the whole blood of asymptomatic individuals by PCR-ELISA and comparison with other infection markers in endemic areas, southern Iran.

Authors:  Abdolvahab Alborzi; Bahman Pourabbas; Frahad Shahian; Jalal Mardaneh; Gholam R Pouladfar; Mazyar Ziyaeyan
Journal:  Am J Trop Med Hyg       Date:  2008-12       Impact factor: 2.345

9.  Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.

Authors:  Ana Paula Fernandes; Míriam Maria Silva Costa; Eduardo Antônio Ferraz Coelho; Marilene Suzan Marques Michalick; Eloísa de Freitas; Maria Norma Melo; Wagner Luiz Tafuri; Daniela de Melo Resende; Vinícius Hermont; Christiane de Freitas Abrantes; Ricardo Tostes Gazzinelli
Journal:  Vaccine       Date:  2008-09-09       Impact factor: 3.641

10.  Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.

Authors:  Amir Mizbani; Tahereh Taheri; Farnaz Zahedifard; Yasaman Taslimi; Hiva Azizi; Kayhan Azadmanesh; Barbara Papadopoulou; Sima Rafati
Journal:  Vaccine       Date:  2009-10-08       Impact factor: 3.641

View more
  3 in total

1.  Assessment of Recombinant A2-Latex Agglutination Test (RA2-LAT) and RA2-ELISA for Detection of Canine Visceral Leishmaniasis: A Comparative Field Study with Direct Agglutination Test in Northwestern Iran.

Authors:  Mahin Farahmand; Hossein Nahrevanian; Vahid Khalaj; Mehdi Mohebali; Mohammad Barati; Sanaz Naderi; Zabih Zarei; Ghader Khalili
Journal:  Iran J Parasitol       Date:  2018 Apr-Jun       Impact factor: 1.012

Review 2.  Protective or Detrimental? Understanding the Role of Host Immunity in Leishmaniasis.

Authors:  Camila Dos Santos Meira; Lashitew Gedamu
Journal:  Microorganisms       Date:  2019-12-13

3.  Application of Recombinant Proteins for Serodiagnosis of Visceral Leishmaniasis in Humans and Dogs.

Authors:  Mahin Farahmand; Hossein Nahrevanian
Journal:  Iran Biomed J       Date:  2016-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.